Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach.

Literature DB >> 25302088

Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach.

James Q Del Rosso¹, Leon Kircik¹, Gary Goldenberg¹, Berman Brian¹.

Abstract

Year: 2014 PMID： 25302088 PMCID： PMC4187997

Source DB: PubMed Journal: J Clin Aesthet Dermatol ISSN： 1941-2789

× No keyword cloud information.

72 in total

1. The effect of increasing fluence on the treatment of actinic keratosis and photodamage by photodynamic therapy with 5-aminolevulinic acid and intense pulsed light.

Authors: Alessandra Haddad; Ivan Dunshee de Abranches Oliveira Santos; Alfredo Gragnani; Lydia Masako Ferreira
Journal: Photomed Laser Surg Date: 2011-06 Impact factor: 2.796

Review 2. The actinic (solar) keratosis: a 21st-century perspective.

Authors: Wendy Fu; Clay J Cockerell
Journal: Arch Dermatol Date: 2003-01

3. Actinic keratoses: a comprehensive update.

Authors: Sherrif F Ibrahim; Marc D Brown
Journal: J Clin Aesthet Dermatol Date: 2009-07

Review 4. The use of topical imiquimod for the treatment of actinic keratosis: a status report.

Authors: James Q Del Rosso
Journal: Cutis Date: 2005-10

Review 5. Current regimens and guideline implications for the treatment of actinic keratosis: proceedings of a clinical roundtable at the 2011 Winter Clinical Dermatology Conference.

Authors: James Q Del Rosso
Journal: Cutis Date: 2011-07

6. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation.

Authors: Brian Berman; Clay J Cockerell
Journal: J Am Acad Dermatol Date: 2013-01 Impact factor: 11.527

7. Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%.

Authors: Eggert Stockfleth; Girish Gupta; Ketty Peris; Selim Aractingi; Rada Dakovic; Agustin Alomar
Journal: Eur J Dermatol Date: 2014 Jan-Feb Impact factor: 3.328

8. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.

Authors: J E Wolf; J R Taylor; E Tschen; S Kang
Journal: Int J Dermatol Date: 2001-11 Impact factor: 2.736

Review 9. Imiquimod applied topically: a novel immune response modifier and new class of drug.

Authors: R L Miller; J F Gerster; M L Owens; H B Slade; M A Tomai
Journal: Int J Immunopharmacol Date: 1999-01

10. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.

Authors: Neil Swanson; William Abramovits; Brian Berman; James Kulp; Darrell S Rigel; Sharon Levy
Journal: J Am Acad Dermatol Date: 2010-02-04 Impact factor: 11.527

6 in total

Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach.

1. The effect of increasing fluence on the treatment of actinic keratosis and photodamage by photodynamic therapy with 5-aminolevulinic acid and intense pulsed light.

Review 2. The actinic (solar) keratosis: a 21st-century perspective.

3. Actinic keratoses: a comprehensive update.

Review 4. The use of topical imiquimod for the treatment of actinic keratosis: a status report.

Review 5. Current regimens and guideline implications for the treatment of actinic keratosis: proceedings of a clinical roundtable at the 2011 Winter Clinical Dermatology Conference.

6. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation.

7. Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%.

8. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.

Review 9. Imiquimod applied topically: a novel immune response modifier and new class of drug.

10. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.

1. Ingenol Mebutate Topical Gel A Status Report On Clinical Use Beyond Actinic Keratosis.

Review 2. Cancer Immunoprevention: Current Status and Future Directions.

Review 3. Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update.

Review 4. Tirbanibulin: Topical Treatment for Actinic Keratosis.

Review 5. Inhibition of TGF-β and NOTCH Signaling by Cutaneous Papillomaviruses.

Review 6. A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies.